Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences to Host In Vivo Gene Editing R&D Day on September 12, 2023

Thursday, August 31, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences, a leader in gene editing, will host an R&D Day focused on in vivo gene editing therapies. The event is set for September 12, 2023, from 9:00 to 11:30 AM ET. This initiative highlights the company's ongoing research efforts and aims to foster collaboration within the industry.
Price reaction · baseline $14.748 (2023-08-30 close) · hit pre-market · 1 other DTIL headline(s) in the window, move may be shared
day 0 close
-5.9%
day 1
-0.9%
day 3 · peak
-10.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences is actively engaging in gene editing research.
  • The R&D Day indicates a commitment to transparency and collaboration.
  • The event is scheduled for a convenient time for stakeholders.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Aug. 31, 2023– Precision BioSciences, Inc. (Nasdaq: DTIL), a gene editing company developing ARCUS®-based in vivo gene editing therapies, today announced that it will host its in vivo gene editing R&D Day on Tuesday, September 12, 2023 from 9:00-11:30 AM ET .

Frequently Asked Questions

What is the date of the R&D Day hosted by Precision BioSciences?

The R&D Day will take place on September 12, 2023.

What time will the R&D Day event occur?

The event is scheduled from 9:00 to 11:30 AM ET.

What is the focus of Precision BioSciences' R&D Day?

The focus will be on in vivo gene editing therapies.

Where is Precision BioSciences located?

Precision BioSciences is based in Durham, North Carolina.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences gene editing R&D Day ARCUS
Last updated: Aug 31, 2023

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →